Clinical Trial Update: Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chidamide in combination with lenalidomide for relapsed or refractory peripheral T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 | Status: UNKNOWN